

**Amendment to the Claims**

The following list of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1-51. (Canceled)

52. (Previously Presented) A method for testing the effectiveness of a therapeutic for treatment of hemostatic dysfunction, comprising (a) monitoring the formation of a complex comprising C reactive protein (CRP) and at least one human lipoprotein selected from the group consisting of very low density lipoprotein (VLDL) and intermediate density lipoprotein (IDL), and (b) correlating the decrease of complex formation with effectiveness of a therapeutic for treatment of hemostatic dysfunction.

53. (Previously Presented) The method of claim 52, wherein the hemostatic dysfunction is disseminated intravascular coagulation (DIC).

54-70. (Canceled)

71. (New) The method of claim 52, wherein the at least one human lipoprotein is a very low density lipoprotein (VLDL).

72. (New) The method of claim 52, wherein the at least one human lipoprotein is an intermediate density lipoprotein (IDL).

73. (New) The method of claim 52, wherein the at least one human lipoprotein further comprises a chylomicron.